The Parkinson’s Foundation estimates that 15,000 people here in Wisconsin have Parkinson’s disease, and that number is only ...

Parkinson’s patients and their caregivers attended the first “Parkinson’s Today:  An Educational Symposium” in Palm Desert on Saturday.  PRO or Parkinson’s Resource Organization teamed up with The ...

Samsung is recognizing Española Valley High School for its student’s efforts to help people dealing with Parkinson’s Disease. Students, in coordination with ...

The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) injection, the first and only ...

The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit.A new study ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...